NEW YORK, March 22 (GenomeWeb News) - Inpharmatica has made its ADME (absorption, distribution, metabolism, and excretion) technology available to GlaxoSmithKline, the company said today.

 

Under the agreement, Inpharmatica, based in London, will apply its ADME technology to a number of GSK's drug discovery programs in the UK and in Europe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.